- Revenue of KRW95.4bn,
operating profit of KRW42.4bn, net
income of KRW37bn… 17%, 51.6%, and 72.7,%,
respectively, year-on-year growth
- With solid performance in global markets such as
Asia-Pacific and Europe, botulinum toxin and HA filler sales
grew by 17.6% and 20%, respectively
- Focus on international expansion in the second half of the
year…Penetrate into the North American market with the first
toxin shipment to the U.S.
SEOUL,
South Korea, Aug. 7, 2024
/PRNewswire/ -- Hugel, a global total medical aesthetics company,
announced consolidated financial statements for the second quarter
of 2024 on August 7th,
reporting revenue of KRW95.4billion,
operating profit of KRW42.4billion,
and net income of KRW37billion.
Thanks to solid performance in global markets, revenue,
operating profit, and net income increased 17%, 51.6%, and 72.7%,
respectively, compared to the same period last year. Notably,
revenue and operating profit surpassed KRW90billion and KRW40billion for the first time, achieving
all-time high quarterly results.
By product, sales of the botulinum toxin "Botulax (Export name:
Letybo)" increased by 17.6% YoY. Hugel maintains its leading
position in domestic market, while in global markets, sales grew in
Europe and key Asia-Pacific regions including China, Thailand, Japan, Taiwan, and Australia. International sales increased by
62% year-on-year with the largest quarterly shipment to
China.
Sales of HA fillers ("THE CHAEUM (Export name: Revolax,
Dermalax, and Persnica)" and "BYRYZN Skinbooster HA") also grew by
20% YoY, achieving steady growth in both domestic and international
markets. As a result of conducting new advertising campaigns in
Korea and continuing academic marketing activities targeting
overseas medical professionals, sales increased evenly across all
regions including the Asia-Pacific, North and South America, and Europe.
Cosmetics sales also grew 10% YoY. The company is expanding
consumer choices by introducing a variety of new products under its
derma cosmetics brand "Wellage" and launching a high-end cosmetics
brand "BYRYZN BR".
Hugel will continue to focus on international expansion in the
second half of the year. Starting with the initial shipment of
"Botulax (Export name: Letybo)" to the U.S. at the end of July,
Hugel plans to focus on stably settling in the North American
market, including Canada.
In addition, the company plans to continuously strengthen its
presence and to increase reliability in Hugel and its product power
in the global medical aesthetics market via conducting various
sales and marketing activities targeting key opinion leaders (KOLs)
in both domestic and key international markets.
A Hugel official stated, "Hugel has achieved all-time high
quarterly revenue and operating profit, driven by anchor products
such as botulinum toxin and HA fillers, demonstrating continued
solid performance across global markets in the second quarter of
this year. We will continue vigorous marketing activities tailored
to local conditions to expand our presence in not only the United States but also in other countries
where Hugel has a presence in markets such as Asia-Pacific and Europe."
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hugel-hit-record-high-quarterly-revenue-and-operating-profit-302216434.html
SOURCE Hugel